Department of Stem Cells and Developmental Biology, Royan Institute for Stem Cell Biology and Technology, Tehran, Iran.
Arch Iran Med. 2011 Jul;14(4):244-9.
Orthotropic liver transplantation (OLT) is the final procedure of both end stage and metabolic liver diseases. Hepatocyte transplantation is an alternative for OLT, but the sources of hepatocytes are limited. Bone marrow mesenchymal stem cells (BM-MSCs) can differentiate into hepatocyte-like cells and are a potential alternative source for hepatocytes. We aimed to investigate the differentiation potential of BM-MSCs into hepatocyte-like cells.
Human BM-MSCs from a healthy donor were cultured and differentiated into hepatocyte-like cells. We investigated the expression of hepatocyte-specific markers in MSC-derived hepatocyte-like cells (MSC-HLC) and evaluated their functionality using metabolic assays.
MSC-HLCs expressed hepatocyte-specific markers at both mRNA and protein levels. In addition, the cells had the ability to uptake low density lipoprotein (LDL), clear ammonia, secrete albumin, and store glycogen. MSC-HLCs were transplanted into a familial hypercholesteromia patient.
Human MSCs can be differentiated into partially functional hepatocyte-like cells. Thus, they could be a potential source for cell therapy in liver disorders.
同种异体肝移植(OLT)是终末期和代谢性肝病的最终治疗手段。 肝细胞移植是 OLT 的替代方法,但肝细胞的来源有限。 骨髓间充质干细胞(BM-MSCs)可以分化为肝样细胞,是肝细胞的潜在替代来源。 我们旨在研究 BM-MSCs 分化为肝样细胞的潜力。
从健康供体中培养和分化 BM-MSCs 为肝样细胞。 我们研究了 MSC 衍生的肝样细胞(MSC-HLC)中肝特异性标志物的表达,并使用代谢测定评估其功能。
MSC-HLC 在 mRNA 和蛋白质水平上均表达肝特异性标志物。 此外,这些细胞具有摄取低密度脂蛋白(LDL)、清除氨、分泌白蛋白和储存糖原的能力。 将 MSC-HLC 移植到家族性高胆固醇血症患者体内。
人 MSCs 可分化为具有部分功能的肝样细胞。 因此,它们可能成为肝脏疾病细胞治疗的潜在来源。